-
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
18 Apr 2024 22:18 GMT
… in combination with Cytarabine achieves preliminary CRc … a European clinical trial
– There are … Drug Designation for the treatment of STS lung mets.
About Moleculin Biotech … , Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical …
-
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
18 Apr 2024 11:00 GMT
… (NASDAQ: BPTH) a biotechnology company leveraging its proprietary … States Food and Drug Administration (FDA) to review patient … cytarabine. However, many patients become resistant to venetoclax treatment. … trial. Dr. Roboz is a professor of medicine and …
-
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
09 Apr 2024 21:15 GMT
… patients in combination with cytarabine, development was halted … medicine and revolutionize the way patients seek and receive treatments … and completion of clinical trials; (ii) risks related … tax laws or rates, pharmaceutical regulations, and other regulations …
-
Successful Treatment of an AML Patient Infected with Hypervirulent ST463 Pseudomonas Aeruginosa Harboring Rare Carbapenem-Resistant Genes blaAFM-1 and blaKPC-2 Following Allogeneic Hematopoietic Stem Cell Transplantation
05 Apr 2024 16:19 GMT
… HSCT) is a crucial treatment for curing hematologic malignancies … further understand the drug-resistance mechanisms of … HAD and intermediate-dose cytarabine, however, the … LY21H290003), Zhejiang Traditional Chinese Medicine Scientific Research Foundation ( …
-
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
25 Mar 2024 15:07 GMT
… in combination with Cytarabine for the treatment of AML is … FDA, the Company may elect to complete this trial … Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical … be replicated in human trials. Although Moleculin believes that …
-
Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
25 Mar 2024 16:29 GMT
… welcome to the Moleculin Biotech 2023 Year-End Conference … a remarkable next generation treatment. Its lack of … with and Cytarabine. Our combination Annamycin plus Cytarabine clinical trial, that … Wally mentioned, FDA approved those five drugs on what we …
-
Moleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AML
25 Mar 2024 13:17 GMT
Moleculin Biotech, Inc., (MBRX) Monday … in combination with Cytarabine for the treatment of subjects with … ).
Annamycin in combination with Cytarabine (AnnAraC) achieved complete response … alternative, regardless of prior treatments or mutations," commented …
-
Why Is Cancer Drug-Developer Nkarta Stock Trading Lower On Friday?
22 Mar 2024 18:28 GMT
… patient enrollment in its clinical trial of NKX101 and deprioritized … lymphodepletion (LD) comprising fludarabine and cytarabine (flu/Ara-C).
… its Phase 1 clinical trial evaluating NKX101 in patients … the clearance by the FDA of the IND application …
-
PTC Therapeutics completes BLA submission to US FDA for Upstaza as a treatment for AADC deficiency
21 Mar 2024 11:52 GMT
… Drug Administration (FDA) for the approval of Upstaza (eladocagene exuparvovec), an investigational treatment … s 50+ pharmaceutical, academic, and biotech partners to bypass … injection of the chemotherapy drug Cytarabine into the ventricles. … and drug trials.
-
FDA Grants Accelerated Approval to Ponatinib Combo in Ph+ ALL
19 Mar 2024 19:14 GMT
… the phase 3 PhALLCON trial (NCT03589326).
A minimal … Common adverse effects in the trial included hepatic dysfunction, rash … alternated between methotrexate and cytarabine, and 11 cycles of … to treatment failure, and overall survival.
According to the FDA, the …